{"preliminary_commentary":{"by_channel":{"x_thread":8,"youtube":3,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03974022\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"WU-KONG1","nct_id":"NCT03974022","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=wu-kong1-nct03974022. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Part A Dose escalation","type":"EXPERIMENTAL"},{"description":null,"label":"Part A Dose expansion cohort 1","type":"EXPERIMENTAL"},{"description":null,"label":"Part A Dose expansion cohort 2","type":"EXPERIMENTAL"},{"description":"Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy","label":"Part A Dose expansion cohort 3","type":"EXPERIMENTAL"},{"description":"Patients with EGFR Exon20ins, previously treated with at least one line of systemic therapy","label":"Part A Dose expansion cohort 4","type":"EXPERIMENTAL"},{"description":"Patients with EGFR Exon20ins, treatment naïve","label":"Part A Dose expansion cohort 5","type":"EXPERIMENTAL"},{"description":null,"label":"Part A Dose expansion cohort 6","type":"EXPERIMENTAL"},{"description":"Patients with EGFR Exon20ins","label":"Part B Dose extension cohort 1","type":"EXPERIMENTAL"},{"description":"Patients with EGFR Exon20ins","label":"Part B Dose extension cohort 2","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":315,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sunvozertinib","otherNames":["DZD9008"],"type":"DRUG"}],"last_update":"2026-01-29","lead_sponsor":"Dizal Pharmaceuticals","official_title":"A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With EGFR or HER2 Mutation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-07-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part A Dose Escalation: Dose Limiting Toxicities (DLTs).","timeFrame":"The DLT observation period is defined as the 28 days after the first multiple dose (up to 36 days from baseline)."},{"measure":"Part B: Objective Response Rate (ORR) According to RECIST 1.1 by an Independent Review Committee (IRC).","timeFrame":"through the study completion, an average of around 1 year for part B"}],"references":[{"citation":"Yang JC, Wang M, Doucet L, Fan Y, Lv D, Sun M, Huang D, Greillier L, Planchard D, Hong Q, Mazieres J, Felip E, Li X, Hu Y, Fang J, Bazhenova L, Ghiringhelli F, Cobo Dols MA, Rodriguez LP, Bearz A, Pellini B, Kim YJ, Bosch-Barrera J, Shim BY, Luo YH, Tiseo M, Yang TY, Carcereny E, Memmott RM, Zalcman G, de Castro Carpeno J, Di Noia V, Parra HS, Streich G, Lee DH, Shum E, Han JY, Jaime JC, Brungs D, John T, D'Arcangelo M, Joaquin AB, Liu G, Antonuzzo L, Hinojal GF, Le X, Zheng L, Janne PA; WU-KONG1B. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). J Clin Oncol. 2025 Oct 10;43(29):3198-3208. doi: 10.1200/JCO-25-00788. Epub 2025 Sep 9.","pmid":"40923280","type":"DERIVED"},{"citation":"Miyamura BV, Mambetsariev I, Fricke J, Arias-Romero J, Cadman K, Shrestha S, Pisick E, Nguyen D, Malhotra J, Reyes A, Salgia R. Current paradigm of EGFRins20 in non-small cell lung cancer: A long way forward. Med. 2025 Sep 12;6(9):100803. doi: 10.1016/j.medj.2025.100803. Epub 2025 Aug 8.","pmid":"40782807","type":"DERIVED"},{"citation":"Luan T, Lin X, Xie X, Yang G, Wang S, Hao J, Zhou C. First case report of sunvozertinib for the treatment of HER2 exon 20 insertion in lung adenocarcinoma. Anticancer Drugs. 2024 Sep 1;35(8):757-760. doi: 10.1097/CAD.0000000000001628. Epub 2024 Jun 26.","pmid":"38924456","type":"DERIVED"}],"start_date":{"date":"2019-07-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)","url":"https://clinicaltrials.gov/study/NCT03974022"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/wu-kong1-nct03974022"}